skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Puff versus Protracted Releases

ORCiD logo [1]
  1. National Security Technologies, LLC, Mercury, Nevada
Publication Date:
Research Org.:
Nevada Test Site/National Security Technologies, LLC (United States)
Sponsoring Org.:
USDOE National Nuclear Security Administration (NNSA), Office of Emergency Operations (NA-40)
OSTI Identifier:
Report Number(s):
DOE Contract Number:
Resource Type:
Resource Relation:
Conference: Assessment Working Group Topical Discussion, National Nuclear Security Administration, Office of Emergency Response, Washington, DC
Country of Publication:
United States
61 RADIATION PROTECTION AND DOSIMETRY; consequence management, radiation plume, radiation puff

Citation Formats

Guss, Paul. Puff versus Protracted Releases. United States: N. p., 2017. Web.
Guss, Paul. Puff versus Protracted Releases. United States.
Guss, Paul. 2017. "Puff versus Protracted Releases". United States. doi:.
title = {Puff versus Protracted Releases},
author = {Guss, Paul},
abstractNote = {},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = 2017,
month = 5

Other availability
Please see Document Availability for additional information on obtaining the full-text document. Library patrons may search WorldCat to identify libraries that hold this conference proceeding.

Save / Share:
  • The rapid identification of contaminant plume sources and their characteristics in urban environments can greatly enhance emergency response efforts. Source identification based on downwind concentration measurements is complicated by the presence of building obstacles that can cause flow diversion and entrainment. While high-resolution computational fluid dynamics (CFD) simulations are available for predicting plume evolution in complex urban geometries, such simulations require large computational effort. We make use of an urban puff model, the Defence Science Technology Laboratory's (Dstl) Urban Dispersion Model (UDM), which employs empirically based puff splitting techniques. UDM enables rapid urban dispersion simulations by combining traditional Gaussian puffmore » modeling with empirically deduced mixing and entrainment approximations. Here we demonstrate the preliminary reconstruction of an atmospheric release event using stochastic sampling algorithms and Bayesian inference together with the rapid UDM urban puff model based on point measurements of concentration. We consider source inversions for both a prototype isolated building and for observations and flow conditions taken during the Joint URBAN 2003 field campaign at Oklahoma City. The Markov Chain Monte Carlo (MCMC) stochastic sampling method is used to determine likely source term parameters and considers both measurement and forward model errors. It should be noted that the stochastic methodology is general and can be used for time-varying release rates and flow conditions as well as nonlinear dispersion problems. The results of inversion indicate the probability of a source being at a particular location with a particular release rate. Uncertainty in observed data, or lack of sufficient data, is inherently reflected in the shape and size of the probability distribution of source term parameters. Although developed and used independently, source inversion with both UDM and a finite-element CFD code can be complementary in determining proper emergency response to an urban release. Ideally, the urban puff model is used to approximate the source location and strength. The more accurate CFD model can then be used to refine the solution.« less
  • Three-dimensional dose-rate/time/ response mathematical surfaces describe radiation effects in lifetime studies of beagles after Intake by injection or inhalation of selected radionuclides (including {alpha}-emitters {sup 226}Ra, {sup 239}Pu, {sup 238}Pu, and {sup 241}Am and {Beta}-emitters {sup 90}Sr, {sup 91}Y, and {sup 144}Ce) and in people after intake of {sup 226}Ra. For each effect t{sub m}=K{sub m}d{sup -s}, where t{sub m} is the median elapsed time to death with the specified effect after intake, d is the time-weighted average absorbed radiation dose-rate to the target organ, K{sub m} is the median distribution coefficient, and s is the negative slope parameter. Usingmore » maximum likelihood survival regression methods, for fatal cancer induction s was found to be one-third for {alpha} radiation and two-thirds for {beta} radiation. Because the slopes of the response curves for high LET {alpha} emitters differ from those for the low LET {Beta} emitters, the observed relative biological effectiveness, RBE({alpha}/{beta}), varies as a function of time-weighted average dose rate. At high dose rates, this radiation-induced cancer RBE({alpha}/{beta}) is small, but as dose rate goes down, the radiation-induced cancer RBE({alpha}/{beta}) rises without limit; actually the RBE({beta}/{alpha}) for producing radiation-induced cancer approaches zero. For example, for {sup 239}Pu dioxide in lung at 0.1 Gy d{sup -1} vs. {sup 90}Sr, the RBE({alpha}/{beta})=5, while at 1 mGy d{sup -1}, RBE({alpha}/{Beta})=50. The bone cancer RBE({alpha}/{beta})=l at 0.16 Gy d{sup -1} but RBE({alpha}/{beta})=30 at 1 mGy d{sup -1} for {sup 226}Ra/{sup 90}Sr in bone. Since {sup 238}Pu and {sup 239}Pu are about 10 times more effective than {sup 226}Ra in producing bone cancer, the apparent RBE({alpha}/{beta})=300 for plutonium in bone at 1 mG d{sup -1}.« less
  • Purpose: To retrospectively compare the acute toxicity, pathologic response, relapse rates, and survival in rectal cancer patients treated with preoperative radiotherapy (RT) and either concurrent capecitabine or concurrent protracted infusion 5-fluorouracil (5-FU). Methods: Between June 2001 and February 2004, 89 patients with nonmetastatic rectal adenocarcinoma were treated with preoperative RT and concurrent capecitabine, followed by mesorectal excision. These patients were individually matched by clinical T and N stage (as determined by endoscopic ultrasound and CT scans) with 89 control patients treated with preoperative RT and concurrent protracted infusion 5-FU between September 1997 and August 2002. Results: In each group, 5more » patients (6%) had Grade 3-4 toxicity during chemoradiotherapy. The pathologic complete response rate was 21% with capecitabine and 12% with protracted infusion 5-FU (p = 0.19). Of the 89 patients in the capecitabine group and 89 in the 5-FU group, 46 (52%) and 55 (62%), respectively, had downstaging of the T stage after chemoradiotherapy (p = 0.20). The estimated 3-year local control (p = 0.15), distant control (p = 0.86), and overall survival (p = 0.12) rate was 94.4%, 86.3%, and 89.8% for patients treated with capecitabine and 98.6%, 86.6%, and 96.4% for patients treated with protracted infusion 5-FU, respectively. Conclusion: Preoperative concurrent capecitabine and concurrent protracted infusion 5-FU were both well tolerated, with similar, low rates of Grade 3-4 acute toxicity. No significant differences were seen in the pathologic response, local and distant recurrence, or overall survival among patients treated with preoperative RT and concurrent capecitabine compared with those treated with RT and concurrent protracted infusion 5-FU.« less
  • Purpose: To examine the long-term outcomes of a randomized trial comparing short (4 months; Arm 1) and long (8 months; Arm 2) neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer. Methods and Materials: Between 1997 and 2001, 276 patients were enrolled and the data from 261 were analyzed. The stratification risk factors were prostate-specific antigen level >20 ng/mL, Gleason score {>=}7, and Stage T3 or more. The intermediate-risk stratum had one factor and the high-risk stratum had two or more. Staging was done from the bone scan and computed tomography findings. The primary endpoint was biochemical failure-free survival. Results:more » The median follow-up was 102 months. The overall survival, biochemical failure-free survival. and prostate cancer-specific survival did not differ significantly between the two treatment arms, overall or at 5 years. The cumulative probability of overall survival at 5 years was 90% (range, 87-92%) in Arm 1 and 83% (range, 80-86%) in Arm 2. The biochemical failure-free survival rate at 5 years was 66% (range, 62-71%) in Arm 1 and 63% (range, 58-67%) in Arm 2. Conclusion: No statistically significant difference was found in biochemical failure-free survival between 4 months and 8 months of neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer.« less